Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.50) by 60 percent. This is a 74.68 percent increase over losses of $(0.79) per share from
Ensysce lost less money than expected this quarter, and made more sales than people predicted. When a company does better than expected, it can mean they're moving in a better direction, even if they're still losing money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.